ArticleOpen forum infectious diseases2023

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Charlotte-Paige Rolle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.